Shaanxi Kanghui Pharmaceutical Co., Ltd.
SSE:603139.SS
26.2 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 561.635 | 672.96 | 491.511 | 442.757 | 414.072 | 431.421 | 375.618 | 367.057 | 381.846 | 379.785 | 375.731 | 328.064 | 276.821 |
| Cost of Revenue
| 388.591 | 489.21 | 292.367 | 234.605 | 215.647 | 222.748 | 182.99 | 155.374 | 162.278 | 161.701 | 159.491 | 138.89 | 117.945 |
| Gross Profit
| 173.044 | 183.75 | 199.145 | 208.152 | 198.424 | 208.674 | 192.629 | 211.684 | 219.568 | 218.084 | 216.241 | 189.174 | 158.876 |
| Gross Profit Ratio
| 0.308 | 0.273 | 0.405 | 0.47 | 0.479 | 0.484 | 0.513 | 0.577 | 0.575 | 0.574 | 0.576 | 0.577 | 0.574 |
| Reseach & Development Expenses
| 8.317 | 23.985 | 12.345 | 10.148 | 10.361 | 8.217 | 6.511 | 6.707 | 6.842 | 6.654 | 6.377 | 14.134 | 11.986 |
| General & Administrative Expenses
| 15.03 | 11.87 | 8.795 | 8.013 | 11.822 | 10.027 | 7.953 | 10.551 | 4.11 | 4.561 | 3.78 | 18.848 | 17.868 |
| Selling & Marketing Expenses
| 99.685 | 121.684 | 138.182 | 138.042 | 116.479 | 123.357 | 104.584 | 108.096 | 114.776 | 111.888 | 111.745 | 95.339 | 84.102 |
| SG&A
| 114.715 | 133.554 | 146.977 | 146.055 | 128.301 | 133.384 | 112.537 | 118.647 | 118.886 | 116.449 | 115.525 | 114.187 | 101.969 |
| Other Expenses
| 173.004 | 88.014 | 28.492 | 24.595 | 16.34 | 18.763 | 3.238 | -0.424 | 2.142 | 0.372 | 0.419 | 1.026 | 0.259 |
| Operating Expenses
| 296.035 | 245.553 | 187.814 | 180.799 | 155.003 | 160.365 | 137.422 | 142.314 | 142.489 | 138.228 | 137.337 | 118.953 | 106.06 |
| Operating Income
| -122.991 | -61.803 | 2.622 | 38.736 | 43.183 | 56.674 | 65.057 | 73.768 | 74.764 | 73.276 | 73.558 | 64.818 | 47.421 |
| Operating Income Ratio
| -0.219 | -0.092 | 0.005 | 0.087 | 0.104 | 0.131 | 0.173 | 0.201 | 0.196 | 0.193 | 0.196 | 0.198 | 0.171 |
| Total Other Income Expenses Net
| 1.45 | 3.859 | -85.365 | -0.146 | 0.362 | -0.808 | 3.47 | -0.424 | 2.138 | 0.09 | 0.412 | 1.026 | -3.392 |
| Income Before Tax
| -121.54 | -57.943 | -82.742 | 38.59 | 43.545 | 55.866 | 68.295 | 73.344 | 76.902 | 73.367 | 73.971 | 65.844 | 47.68 |
| Income Before Tax Ratio
| -0.216 | -0.086 | -0.168 | 0.087 | 0.105 | 0.129 | 0.182 | 0.2 | 0.201 | 0.193 | 0.197 | 0.201 | 0.172 |
| Income Tax Expense
| -9.543 | -7.168 | -5.957 | 5.593 | 7.087 | 9.797 | 10.53 | 10.161 | 11.668 | 11.162 | 11.229 | 10.022 | 7.282 |
| Net Income
| -89.626 | -26.159 | -76.785 | 36.481 | 34.114 | 42.763 | 55.629 | 63.02 | 65.234 | 62.205 | 62.742 | 55.822 | 40.398 |
| Net Income Ratio
| -0.16 | -0.039 | -0.156 | 0.082 | 0.082 | 0.099 | 0.148 | 0.172 | 0.171 | 0.164 | 0.167 | 0.17 | 0.146 |
| EPS
| -0.9 | -0.26 | -0.77 | 0.37 | 0.34 | 0.43 | 0.56 | 0.69 | 0.87 | 0.83 | 0.84 | 0.77 | 0.61 |
| EPS Diluted
| -0.9 | -0.26 | -0.77 | 0.37 | 0.34 | 0.43 | 0.56 | 0.69 | 0.87 | 0.83 | 0.84 | 0.77 | 0.61 |
| EBITDA
| -26.862 | 3.23 | -31.258 | 60.39 | 58.119 | 68.821 | 79.794 | 84.672 | 88.676 | 84.567 | 85.088 | 76.972 | 54.56 |
| EBITDA Ratio
| -0.048 | 0.005 | -0.064 | 0.136 | 0.14 | 0.16 | 0.212 | 0.231 | 0.232 | 0.223 | 0.226 | 0.235 | 0.197 |